Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus

Archives of Surgery

Volumn 139, Issue 7, 2004, Pages 712-717

  Hamoui, Nahid ^a   Peters, Jeffrey H ^a,b   Schneider, Sylke ^a   Uchida, Kazumi ^a   Yang, Dongyun ^a   Valboehmer, Daniel ^a   Hagen, Jeffrey A ^a   DeMeester, Steven R ^a   DeMeester, Tom R ^a   Danenberg, Kathleen ^a   Danenberg, Peter ^a   Little, Alex G ^b   Peters, ^b   Velanovich, Vic ^b   Joehl, Raymond J ^b   Peralta, Elizabeth ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Department of Surgery ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEONECTIN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CARCINOGENESIS; DYSPLASIA; ESOPHAGITIS; ESOPHAGUS BIOPSY; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; METAPLASIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SQUAMOUS EPITHELIUM; STOMACH ACID;

ADULT; AGED; BARRETT ESOPHAGUS; CYCLOOXYGENASE 2; DISEASE PROGRESSION; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION; HUMANS; HYDROGEN-ION CONCENTRATION; ISOENZYMES; MALE; MEMBRANE PROTEINS; METAPLASIA; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 3042744208     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.139.7.712     Document Type: Article

References (24)

1. Lagergren J, Bergstrom R, Lingren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-831.
2. Iascone C, DeMeester TR, Little AG, Skinner DB. Barrett's esophagus: functional assessment, proposed pathogenesis and surgical therapy. Arch Surg. 1983;118:543-549.
3. Kauer WK, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone: the need for surgical therapy re-emphasized. Ann Surg. 1995;222:525-531.
4. Iljima K, Henry E, Moriya A, Wirz A, Kelman AW, McColl KE. Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology. 2002;122:1248-1257.
5. Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and cardia. J Natl Cancer Inst. 1997;89:1277-1284.
6. Jenkins GJ, Doak SH, Parry JM, D'Souza FR, Griffiths AP, Baxter JN. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg. 2002;89:824-837.
7. Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett's adenocarcinoma. Ann Surg. 2001;233:322-337.
8. Gatenby RA, Vincent TL. An evolutionary model of carcinogenesis. Cancer Res. 2003;63:6212-6220.
9. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
10. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994.
11. Gibson UE, Heid CA, Williams PM. A novel method for real-time quantitative RT-PCR. Genome Res. 1996;6:995-1001.
12. Heath E.I., Canto MI, Wu TT, et al. Chemoprevention for Barrett's esophagus trial: design and outcome measures. Dis Esophagus. 2003;16:177-186.
13. Zhang F, Altorki NK, Wu Y, Soslow RA, Sukbbaramaiah K, Dannenberg AJ. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology. 2001;121:1391-1399.
14. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopolous G. Cyclooxygenase-2 expression in Barrett's esophagus and adenocarcinoma; ex-vivo induction by bile salts and acid exposure. Gastroenterology. 2000;118:487-496.
15. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2 [review]. Annu Rev Pharmacol Toxicol 1998;38:97-120.
16. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol. 1996;270:G393-G400.
17. DuBois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease [review]. FASEB J. 1998;12:1063-1073.
18. Herschman HR. Prostaglandin synthase 2 [review]. Biochim Biophys Acta. 1996;1299:125-140.
19. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493-501.
20. Tsujii M, Kawan S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997;94:3336-3340.
21. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-716.
22. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 1998;58:2929-2934.
23. Zimmerman KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999;59:198-204.
24. Menges M, Michaeli B, Pueschel W, Zeitz M, Meese E. The influence of the suppression of gastroesophageal reflux on the gene expression pattern in Barrett's esophagus. Int J Oncol. 2002;20:1323-1329.